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Abstract 
Purpose of the review: Exacerbations of bronchiectasis have a major impact on quality of life, 
healthcare costs and long term risk of complications. Preventing exacerbations is one of the major 
goals of treatment. Bronchiectasis is increasingly recognised and the impact of bronchiectasis 
exacerbations on daily clinical practice is also increasing. 
Recent findings: Preventing bronchiectasis exacerbations is dependent on appropriate risk 
assessment, identifying the patients at highest risk in order to rationally target preventative 
therapies. Inhaled and oral antibiotic treatments can target chronic bacterial infection which is one 
of the major risk factors for exacerbation. Although the data is weak, airway clearance is an 
important part of long term management including in patients with frequent exacerbations. Anti-
inflammatory therapies such as inhaled corticosteroids do not currently have a major role outside 
co-morbid COPD and asthma, but further studies are required.  
Summary: Treatment of acute exacerbations involves prompt administration of antibiotic therapy 
with usually 14 days of oral, or for severe exacerbations, intravenous antibiotics. The role of 
corticosteroids is not established and there is little data on the optimal management approach for 
acute exacerbations. Home intravenous therapy can reduce healthcare costs and improve patient 
satisfaction with care. A number of large randomized controlled trials are currently enrolling or have 
recently completed raising the possibility that the treatment paradigm may change in the near 
future.  
 
 
 
 
 
  
Introduction 
Bronchiectasis is increasing in prevalence worldwide with most recent data from Spain indicating a 
rate of 362 per 100,000 to add to data from the UK indicating rates of 486 per 100,000 in men and 
566 per year in women.(1,2) Hospitalisations are increasing year on year in the UK, Germany, New 
Zealand and in other countries.(3,4) Navaratnam also demonstrated an increase in admissions to ICU 
for exacerbations of bronchiectasis of 8% per year in the UK.(5)  
Bronchiectasis is a term used both to refer to a radiological appearance, defined as abnormal and 
usually permanent dilation of the bronchi, but when used to describe a disease should be defined by 
the presence of the radiological appearance plus a clinical syndrome consisting of cough, sputum 
production and recurrent respiratory tract infections.(6,7) The combination is sometimes referred to 
as clinically significant bronchiectasis. (8) 
Bronchiectasis is a common finding in patients with chronic respiratory diseases such as COPD and 
asthma.(9-11) The significant of bronchiectasis in these patients groups is not fully understood and 
may represent a consequence of the inflammation in these disorders, a misdiagnosis (where a 
patient with a primary process leading to bronchiectasis is misdiagnosed with COPD or asthma), or a 
co-morbidity where two different processes co-exist in the same patient.(9) The situation is 
complicated by the fact that bronchiectasis is usually defined the bronchial-arterial ratio (B-A ratio). 
At any level on CT, the bronchial diameter should be less than the adjacent vessel.(12-14) A ratio >1 
is usually taken to indicate bronchiectasis. In independent investigations Tan et al, has shown that 
bronchiectasis was present in 19.9% of normal never smoking controls without respiratory 
symptoms, 19.9% of smokers, 14.1% of patients with mild COPD, 22% of patients with moderate 
COPD and 35.1% of patients with severe or very severe COPD.(14) This indicates that our definition 
of bronchiectasis may be too sensitive as mild increase in the B-A ratio is observed in 20% of healthy 
controls, and therefore the true rate of pathological dilatation may be exaggerated.(14)  
Dias et al recently demonstrated that in the majority of cases of increased B-A ratio in COPD 
patients, the change in the ratio was due to a reduced size of the blood vessel. These patients 
therefore do not strictly have bronchiectasis, since the name requires dilation of the bronchi.(15) 
These data are presented here to remind the reader that the following recommendations and data 
refer to clinically significant bronchiectasis only, and should not be applied to the broad range of 
individuals with an abnormal B-A ratio without the corresponding clinical features.  
 
Exacerbations of bronchiectasis 
Even within the definition of clinically significant bronchiectasis, the disease is highly heterogeneous 
in terms of causes, impact and outcomes.(16-19) Up to 60% of cases are idiopathic, with post-
infection being recorded as the most frequent underlying “cause”. Less frequent causes such as 
allergic bronchopulmonary aspergillosis, connective tissue disease, non-tuberculous mycobacterial 
disease and immunodeficiency must be identified and treated as they usually require a specific 
treatment not described below.(20-23) Once the initial identification and treatment of underlying 
causes has been performed, the disease still presents individual “phenotypes”.(24) 
Exacerbations of bronchiectasis typically presenting with a combination of increasing cough, sputum 
production, increasing sputum purulence, malaise, fever or worsening breathlessness. There is no 
universally accepted definition to date and an exacerbation can be highly different between 
individuals. 
What causes exacerbation is uncertain. Viruses have been identified frequently in bronchiectasis. 
Gao et al studied bronchiectasis exacerbations and found 49% of patients had viruses in 
nasopharyngeal swab or sputum at exacerbation compared to 18.9% of patients when stable.(25) 
Bacteria are frequently isolated at exacerbation, but are also seen in sputum cultures from 70% of 
patients when clinically stable.(26-28) It is not known the extent to which increases in bacterial load, 
changes in bacterial strain or changes in the composition of the airway microbiome might explain 
the development of exacerbations of bronchiectasis. Tunney et al studied the airway microbiome 
using 16s rRNA sequencing to obtain a global view of the microorganisms in sputum in stable 
bronchiectasis and exacerbations and show relatively little change at exacerbation, with a trend 
towards a decrease in microbial diversity.(29) The role of fungi is unknown.  
Clinical predictors of exacerbation have been defined. We developed a clinical prediction rule for 
bronchiectasis, the bronchiectasis severity index (BSI) which identifies patients at higher risk of 
mortality, severe exacerbations, outpatient exacerbations and worse quality of life.(30-32) In a 
multivariable analysis of the predictors of severe exacerbatons the strongest predictors were a prior 
history of severe exacerbations (HR 13.5 95% CI 9.40-19.5), FEV1 <30% predicted (HR 1.52 95% CI 
1.03-2.25), MRC dyspnoea score >3 (HR 2.4 95% CI 1.7-3.5), Pseudomonas aeruginosa colonisation 
(HR 2.2 95% CI 1.4-3.4), infection with other organisms (HR 1.7 95% CI 1.1-2.4) and greater 
radiological extent of disease (HR 1.5 95% CI 1.0-2.2). (30) Therefore more extensive disease, 
determined by radiology or lung function, and chronic infection with bacteria are the primary 
predictors of frequent exacerbations. Since chronic infection is the major modifiable risk factor, 
since explains why a priority in clinical management is to suppress or eradicate chronic infection.(33) 
P. aeruginosa is a key pathogen, being present in 10-40% of patients depending on the population 
studied.(30-33) It is well known as a determinant of poor outcome in cystic fibrosis and the 
eradication or suppression of P. aeruginosa is a standard of care in CF.(34-37) In bronchiectasis, 
predominantly European data shows that chronic infection with P. aeruginosa increases the risk of 
death by 3-fold, increases the risk of hospital admission by 7-fold and is also associated with worse 
lung function and a worse quality of life. (38) 
Bacteria drive neutrophilic inflammation, with higher bacterial loads being associated with more 
inflammation and also being associated with a higher frequency of exacerbations.(38) A recent 
prospective study of 381 patients examined the key neutrophil biomarker neutrophil elastase and 
found a clear association between elastase activity and both time to the next exacerbation and 
frequency of exacerbations.(39) The linked biomarker desmosine was independently associated with 
an increased risk of severe exacerbations.(39) It is not known the extent to which other types of 
airway inflammation such as eosinophilic inflammation, impact on bronchiectasis exacerbations, but 
there is clearly a population without neutrophilic disease that still have frequent exacerbations. 
Co-morbidities are also important in both disease severity and the risk of exacerbations.(40,41) A 
recent prospective study from the EMBARC network across Europe showed that in 986 patients the 
strongest predictor of 5-year mortality was having multiple co-morbidities and that patients with 
greater high risk co-morbidities (using a newly developed and validated bronchiectasis aetiology and 
co-morbidity index- BACI) also had a higher frequency of exacerbations.(40) Whether this is 
mediated by increased systemic and airway inflammation associated with co-morbidities or whether 
this is due to some exacerbations being due directly to decompensated co-morbidities such as heart 
failure and cardiovascular disease is unclear. Bronchiectasis appears to increase the risk of 
cardiovascular disease and cardiovascular complications.(41) 
Figure 1 shows some of the known influences on exacerbation susceptibility 
Brill et al have provided the most detailed study of the impact and symptom burden at exacerbation. 
In 32 BE patients completing diary cards, patients had an average of 4 days of symptoms prior to 
treatment and the average duration of symptoms was 16 days.(42) 16% did not recovery by day 35 
indicating a significant number of patients that experience a prolonged “exacerbation recovery” 
period where health status is significantly worse than prior to the exacerbation.(42) There is 
relatively little data on how to enhance recovery and preserve health status post-exacerbation. 
Prevention of exacerbations 
Figure 1 provides a useful framework for the treatment of exacerbations. Bacterial infection is 
targeted with prolonged antibiotics. Co-morbidities such as cardiovascular disease or underlying 
causes such as ABPA should be treated. Airway clearance should be optimised and patients should 
be vaccinated against influenza virus.  
 
Antibiotic therapies 
Controlling chronic bacterial infection reduces inflammation and there is increasing evidence that 
prolonged antibiotic treatment can improve clinical outcomes.(38) 
Inhaled antibiotics are widely used in cystic fibrosis bronchiectasis but none are licensed for use in 
bronchiectasis excluding CF.(43) The most widely used agents are colistin, gentamicin and 
tobramycin in Europe.(44) Colistin has been tested in a 6 month randomized controlled trial by 
Haworth et al. The trial enrolled 144 patients randomized to colistin or placebo. Median time to 
exacerbation was 111 days in the placebo group and 165 days in the active group, which narrowly 
missed statistical significant (p=0.1).(45) The i-Neb device allows monitoring of compliance the result 
was statistically significant in the compliant population. There was also a marked improvement in 
quality of life using the St.Georges Respiratory Questionnaire (SGRQ).(45) 
Tobramycin has been tested in a number of small randomized trials with mixed results. Although 
some clinical benefits have been noted, a high rate of bronchospasm has also been observed which 
is a potential problem with all inhaled antibiotics.(46) 
Brodt performed a meta-analysis of all available inhaled antibiotic trials and reported a significant 
reduction in exacerbation risk (RR 0.72 95%I CI 0.55-0.94), while also noting a small increase in 
antibiotic resistance and a rate of bronchospasm of 10%.(47) 
While this estimate is useful, the appropriateness of pooling all available data should be questioned. 
Results have been highly variable between different inhaled antibiotic drugs, with no benefit in 
terms of exacerbations with aztreonam, for example, when tested against placebo in a population of 
patients with Gram-negative airway infection.(48) Therefore the data for each individual drug should 
be considered both in terms of safety and efficacy before choosing the optimal treatment for the 
patient. 
Most patients receiving inhaled antibiotics in real-life clinical practice have a history of P. aeruginosa 
infection and have a history of frequent exacerbations.(44) 
Long term oral antibiotic treatment has advantages in terms of convenience and compliance 
compared to inhaled antibiotics but also carries increased risks of systemic side effects and antibiotic 
resistance.(49-51) The most intensively studied are the macrolides, although it remains a subject of 
debate as to whether these function primarily as an antibiotic or an anti-inflammatory agent. 3 
randomized controlled trials of 6-12 months treatment in bronchiectasis patients with a history of 
exacerbations have unequivocally shown a reduction in the frequency of exacerbations.(49-51) Up 
to 20% of patients experience gastrointestinal side effects with azithromycin or erythromycin, and 
there are reports of hearing loss and prolongation of the QT interval. Patients should be carefully 
screened for NTM infection to avoid the potential consequences of macrolide resistance NTM. 
Tetracyclines and penicillins have also been tested in historical studies and are occasionally used at 
low doses as prophylactic therapy, for example in patients with H. influenzae infection. The data to 
support this is limited.(52-54) 
Patients who continue to exacerbate despite an inhaled antibiotic may benefit from combined 
treatment with an oral and inhaled antibiotic. Notably, macrolides inhibit P. aeruginosa virulence 
factors and may also have some antimicrobial effect and so combined treatment may be beneficial 
in patients with P. aeruginosa infection.(55,56) 
Similarly, patients who continue to exacerbate despite macrolide therapy may benefit from an 
alternative oral antibiotic or a trial of an inhaled antibiotic.  
Patients who have failed to respond to trials of prolonged antibiotic treatment, either because of 
poor tolerance or lack of efficacy may benefit from 6-8 week intravenous antibiotic treatments.(57) 
A schematic of antimicrobial treatment is shown in figure 2.  
P. aeruginosa eradication treatment with oral ciprofloxacin for 2 weeks or intravenous 
antipseudomonal antibiotics plus inhaled antibiotics is standard of care on the first isolation of P. 
aeruginosa in CF patients and it is the authors practice as well as guideline recommendations to 
attempt eradication on first isolation in patients with bronchiectasis.(58) 
 
Anti-inflammatory therapies 
Inhaled corticosteroids are the most frequently used therapy for patients with bronchiectasis 
despite an absence of high quality randomized controlled trial evidence.(59) A Cochrane review 
found no clear patient benefit from the small trials that have been conducted and side effects 
include a possible increase risk of pneumonia as has been observed in COPD.(60-62) Inhaled 
corticosteroids should be reserved for patients with bronchiectasis and COPD, or those with 
asthma.(63)  
 
Vaccination 
Patients with bronchiectasis should receive influenza vaccination, since they are at higher risk of 
influenza complications and influenza can be associated with exacerbations. Guidelines also 
recommend that patients with bronchiectasis should receive pneumococcal vaccination.  
 
Chest clearance and mucoactive drugs 
All patients with bronchiectasis should be trained to perform airway clearance.(64) Mucoactive 
drugs may be helpful in patients expectorating large volumes of sputum and with exacerbations 
despite adequate airway clearance techniques. Options include isotonic or hypertonic saline, 
carbocisteine and inhaled dry powder mannitol.(65-67) Two randomized trials of mannitol failed to 
achieve their primary end-point.(66,67) A comparison between isotonic and hypertonic saline in 
found no differences in terms of exacerbations or quality of life.(65) Larger studies are planned.  
 
Treatment of exacerbations 
There are very few studies of the treatment of acute exacerbations of bronchiectasis.(54) 
Exacerbations are classified into those requiring antibiotic treatment, and those severe 
exacerbations requiring admission to hospital and intravenous antibiotic treatment. 14-days of 
antibiotics are recommended with high doses given the high bacterial loads associated with 
bronchiectasis, although such recommendations may change in the future as data emerges.(54) 
Intravenous antibiotics are indicated for patients with respiratory failure, sepsis, inability to take oral 
therapy or for patients who have failed to respond to an adequate oral course of therapy or who 
isolate a pathogen resistant to all available oral drugs.(54)  
Exacerbations due to P. aeruginosa can be treated with high dose oral ciprofloxacin if mild, for 14 
days. If admitted to hospital, there is no evidence that combination antibiotic treatments are 
superior to monotherapy with an effective anti-pseudomonal antibiotic.(54) The authors practice is 
to use monotherapy for older patients at higher risk of adverse effects, particularly from 
aminoglycosides (68), while using combination treatments for patients with drug resistance P. 
aeruginosa to attempt to limit the further development of resistance. Adjunctive inhaled antibiotics 
have been attempted with limited benefit.(69) 
Oral corticosteroids are not indicated for bronchiectasis exacerbations, unless COPD or asthma are 
present.  
Patients should intensify chest clearance techniques during an exacerbation and a review by a 
specialist physiotherapist during hospitalisation is valuable. Hydration with intravenous fluids may 
also aid airway clearance during inpatient admissions.  
 
Future directions 
Two large randomized controlled trials of inhaled antibiotics will report in 2017 and may change the 
treatment paradigm for bronchiectasis.(70,71) Alternatives to antibiotics are urgently needed and 
De Soyza recently reported the results of a novel anti-inflammatory, the CXCR2 antagonist AZD5069 
in bronchiectasis. The study showed a reduction in the primary outcome of sputum neutrophil count 
(by 69%) without a reduction in exacerbations, for which the study was not powered.(72) There was 
an increase in adverse effects including pneumonia suggesting that reducing neutrophil counts may 
be harmful in some patients with bronchiectasis.(72) Further development of anti-inflammatory 
therapies that modulate neutrophil function rather than reducing neutrophil numbers may have 
greater success.  
A recent statement from the European Bronchiectasis Network (EMBARC) has listed key research 
priorities in the field including a number relating to exacerbations.(73) Large multicentre networks 
such as EMBARC and the US bronchiectasis registry have the potential to generate data that will 
answer some of the outstanding questions above regarding bronchiectasis exacerbations, as there 
are a limited number of bronchiectasis RCTs.(74.75) The first results of the US Registry have recently 
been published with 1826 patients enrolled from 2008-2014. 79% of patients were female and 63% 
had a history of NTM isolation of NTM disease. P. aeruginosa was the most frequently isolated 
bacterial pathogen. (74) Longitudinal data to compare treatment outcomes and identify best 
practice will be the most informative and are awaited. 
 
Conclusion 
Bronchiectasis exacerbations are common, with an important healthcare burden. Treatment 
pathways for acute exacerbations are poorly defined but there are now a number of therapies with 
evidence to support a role in prevention of exacerbations. Ongoing registries and randomized trials 
are likely to provide future guidelines with a stronger evidence based approach to the disease.  
 
  
1. Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, Simonet P, Miravitlles M.. 
Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. 
Respir Med. 2016;121:26-31. doi: 10.1016/j.rmed.2016.10.014. 
2. Quint JK, Millett ER, Joshu M et al. Changes in the incidence, prevalence and mortality of 
bronchiectasis in the UK from 2004-2013: a population based cohort study. Eur Respir J 
2016;47(1):186-93 
*A comprehensive epidemiological study demonstrating the rapid rise in reported prevalence 
of bronchiectasis in the UK 
3. Ringshausen FC, de Roux A, Diel R et al. Bronchiectasis in Germany: a population-based 
estimation of disease prevalence. Eur Respir J 2015; 46(6):1805-7. 
4. Bibby S, Milne R, Beasley R Hospital admissions for non-cystic fibrosis bronchiectasis in New 
Zealand. N Z Med J. 2015 Sep 4;128(1421):30-8. 
5. Navaratnam V, Muirhead CR, Hubbard RB, De Soyza A Critical care admission trends and 
outcomes in individuals with bronchiectasis in the UK. QJM. 2016 Aug;109(8):523-6. doi: 
10.1093/qjmed/hcv206 
6. Amaral RH, Schuler Nin C, De Souza VV et al. Computed tomography in the diagnosis of 
bronchiectasis. Eur Respir J 2015;46(2):576-7. 
7. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-
cystic fibrosis bronchiectasis. Mol Immunol 2013;55:27–34. 
8. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Fardon TC, Finch S, Mateus EF, Garcia-
Bellmunt L, Castillo D, Vidal S, Sanchez-Reus F, Restrepo MI, Chalmers JD. Secreted mucins 
and airway bacterial colonization in non-CF bronchiectasis. Respirology; 20(7):1082-8.  
9. Blasi F, Chalmers JD, Aliberti S. COPD and bronchiectasis: phenotype, endotype or 
comorbidity. COPD 2014;11(6):603-4. 
10. De Marco R, Marcon A, Rossi A et al. Asthma, COPD and overlap syndrome: a longitudinal 
study in young European adults. Eur Respir J 2015;46(3):671-9. 
11. Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. Eur Respir J 
2016;47(6):1680-6. 
12. Matsuoka S, Uchiyama K, Shima H, et al. Bronchoarterial ratio and bronchial wall thickness 
on high-resolution CT in asymptomatic subjects: correlation with age and smoking. AJR Am J 
Roentgenol 2003; 180: 513–518  
13. Reiff DB, Wells AU, Carr DH et al. CT findings in bronchiectasis: limited value in distinguishing 
between idiopathic and specific types. AJR Am J Roentgenol. 1995;165(2):261-7. 
14. Tan WC, Hague CJ, Leipsic J. Findings on thoracic computed tomography scans and 
respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a 
population-based cohort study. Plos One 2016;11(11):e0166745. 
*an important study that identifies the relationship between smoking, COPD and 
radiological bronchiectasis.  
15. Diaz AA, Young TP, Maselli DJ, Quantitative CT measures of bronchiectasis in smokers. Chest 
2016 in press.  
**an outstanding paper that questions the current definition of bronchiectasis dependent 
on bronchial-arterial ratio- demonstrating that most COPD associated bronchiectasis is due 
to a reduced size of the blood vessel.  
16. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, Polverino E, Van 
de Kerkhove C, Rutherford R, Davidson J, Rosales E, Pesci A, Restrepo MI, Aliberti S. Etiology 
of non-cystic fibrosis bronchiectasis in adults and its relationship to severity. Ann Am Thorac 
Soc 2015; 12(12):1764-70 
17. Hurst JR, Elborn JS, De Soyza A. COPD-bronchiectasis overlap syndrome. Eur Respir J 
2015;45(2):310-3. 
18. Bellelli G, Chalmers JD, Sotgiu G, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Skrbic D, 
Lombi A, Pane F, Obradovic D, Fardon TC, Rutherford RM, Pesci A, Aliberti S. 
Characterisation of bronchiectasis in the elderly. Respir Med 2016;119:13-19.  
19. Chalmers JD, McDonnell MJ, Rutherford R, Davidson J, Finch S, Crichton M, Dupont L, Hill AT, 
Fardon TC, De Soyza A, Aliberti S, Goeminne P. The generalizability of bronchiectasis 
randomized controlled trials: a multicentre cohort study. Respir Med 2016;112:51-8. 
20. Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, Marruchella A, Gori A, 
Blasi F, Codecasa L, Pesci A, Chalmers JD, Loebinger MR, Aliberti S. Characterizing non-
tuberculous Mycobacteria infection in bronchiectasis. Int J Mol Sci 2016; 17(11):pii E1913 
21. Agarwal R, Aggarwal AN, Dhooria S et al. A randomized trial of glucocorticoids in acute-sstage 
allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 2016;47(2):490-8. 
22. Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity 
and related disorders. Eur Respir J 2015;46(6):1781-95. 
23. Suarez-Cuartin G, Chalmers JD, Sibila O. Diagnostic challenges of bronchiectasis. Respir Med 
2016;116:70-7. 
24. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Fardon TC, Rutherford 
R, Pesci A, Restrepo MI, Sotgiu G, Chalmers JD. Clinical phenotypes in adult patients with 
bronchiectasis. Eur Respir J 2016;47(4):1113-22. 
25. Gao YH, Guan WJ, Xu G et al. The role fo viral infection in pulmonary exacerbations of 
bronchiectasis in adults: a prospective study. Chest 2015;14&(6):1635-43. 
26. Chalmers JD, McHugh BJ, Doherty CJ, Govan JR, Hill AT. Vitamin-D deficiency is associated 
with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 
2012; 68(1):39-47.  
27. Mandal P, Chalmers JD, Graham C, Harley C, Sidhu MK, Doherty C, Govan JW, Sethi T, 
Davison DJ, Rossi AG, Hill AT. Atorvastatin as a stable treatment in bronchiectasis: a 
randomised controlled trial. Lancet Respiratory Medicine 2014;2(6):455-63. 
28. Chalmers JD, McHugh BJ, Doherty C et al. Mannose binding lectin deficiency and disease 
severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med 
2013;1(3):224-32. 
29. Tunney MM, Einarsson GG, Wei L et al. Lung microbiota and bacterial abundance in patients 
with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care 
Med 2013;187(10):1118-26. 
30. Chalmers JD, Goeminne P, Aliberti S, McDonnell M, Lonni S, Davidson J, Poppelwell L, Salih 
W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT. Derivation and validation of the 
bronchiectasis severity index: an international multicentre observational study. Am J Respir 
Crit Care Med 2014;189(5):576-85. 
31. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, Ward C, Laffey 
JG, Finch S, Pesci A, Dupont LJ, Fardon TC, Skrbic D, Obradovic D, Cowman S, Loebinger MR, 
Rutherford RM, De Soyza A, Chalmers JD. Multidimensional severity assessment in 
bronchiectasis- analysis of 7 European Cohorts. Thorax 2016 in press. 
*one of the largest international bronchiectasis datasets ever reported, providing a 
comphrensive view of disease severity and disease impact. 
32. Ellis HC, Cowman S, Fernandes M, Wilson R, Loebinger MR. Predicting mortality in 
bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. 
Eur Respir J 2016;47(2):482-9. 
33. Chalmers JD, Aliberti S, Blasi F. Treatment of Bronchiectasis in Adults. Eur Respir J 2015; 
45(5):1446-62. 
34. Burgel PR, Bellis G, Olesen HV et al. Future trends in cystic fibrosis demography in 34 
European Countries. Eur Respir J 2015;46(1):133-41. 
35. Stephenson AL, Tom M, Berthiaume Y et al. A contemporary survival analysis of individuals 
with cystic fibrosis: a cohort study. Eur Respir J 2015; 45(3):670-9. 
36. Barr HL, Halliday N, Cámara M, et al. Pseudomonas aeruginosa quorum sensing molecules 
correlate with clinical status in cystic fibrosis. Eur Respir J 2015;46(4):1046-54. 
37. Finch S, McDonnell MJ, Abo-Leyah H et al. A comprehensive analysis of the impact of 
Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis.Ann Am Thorac 
Soc 2015;12(11).  
38. Chalmers JD, Smith MP, McHugh B, Doherty C, Govan JRW, Hill AT. Short and long term 
antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J 
Respir Crit Care Med. 2012; 186(7):657-65. 
39. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel K, 
Elborn JS, Walker B, Martin SL, Marshall SE, Huang JTJ, Fardon TC. Neutrophil elastase 
activity is associated with exacerbations and lung function decline in bronchiectasis. Am J 
Respir Crit Care Med 2017 in press.  
40. McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Pesci A, Dupont LJ, Fardon TC, Wilson 
R, Loebinger MR, Skrbic D, Obradovic D, De Soyza A, Ward C, Laffey JG, Rutherford R, 
Chalmers JD. Co-morbidities and the risk of mortality in patients with bronchiectasis. An 
international cohort study. Lancet Respiratory Medicine 2016 in press.  
41. Navaratnam V, Millett ER, Hurst JR, Thomas SL, Smeeth L, Hubbard RB, Brown J, Quint JK. 
Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax. 
2016 Aug 29. pii: thoraxjnl-2015-208188. doi: 10.1136/thoraxjnl-2015-208188 
42. Brill SE, Patel AR, Singh R et al. Lung function, symptoms and inflammation during 
exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. 
Respir Res 2015;16:16. 
43. Elborn JS, Bell SC, Madge SL et al, Report of the European Respiratory Society/European 
Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 
2016;47(2):420-8.  
44. EMBARC registry data, accessible at www.bronchiectasis.eu  
45. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with 
bronchiectasis and chronic pseudomonas aeruginosa infection. Am J Respir Crit Care Med 
2014; 189(8):975-82. 
46. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum 
Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 
2000;162:481–5. 
47. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable on-cystic fibrosis bronchiectasis: 
a systematic review. Eur Respir J 2014;44(2):382-93. 
48. Barker AF, O’Donnell AE, Flume P et al. Aztreonam for inhalation solution in patients with 
non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, 
placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9): 738-49. 
49. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EHJ, Koppers RJH, van der Werf TS, 
Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations 
among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. 
JAMA 2013;309:1251–9. 
50. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash 
P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations 
among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled 
trial. JAMA 2013;309:1260–7. 
51. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, 
Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic 
fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. 
Lancet 2012; 380(9842):660-7.  
52. Hill SL, Burnett D, Hewetson KA, et al. The response of patients with purulent bronchiectasis 
to antibiotics for four months. Q J Med 1988;66:163-73. 
53. Hill SL, Morrison HM, Burnett D, et al. Short term response of patients with bronchiectasis to 
treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 
1986;41:559-65. 
54. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. 
Thorax 2010; 65:suppl 1:i1-58. 
55. Burr LD, Rogers GB, Chen AC et al. Macrolide Treatment Inhibits Pseudomonas aeruginosa 
Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis 
and Low-Dose Erythromycin Study Trial. Ann Am Thorac Soc. 2016 Oct;13(10):1697-1703. 
*small study, but confirms that macrolides have activity against P. aeruginosa in 
bronchiectasis 
56. Guillon A, Jouan Y, Brea D, et al. Neutrophil proteases alter the interleukin-22-receptor 
dependent lung antimicrobial defence. Eur Respir J 2015;46(3):771-82. 
57. Mandal P, Sidhu MK, Donaldson LS, Chalmers JD, Smith MP, Turnbull K, Scott J, Hill AT. Eight-
weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33.  
58. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of 
Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir 
Med 2012; 106(3):356-60. 
59. Goyal V, Chang AB, Combined inhaled corticosteroids and long acting beta2-agonists for 
children and adults with bronchiectasis. Cochrane Database Syst Rev 2014;6:CD010327. 
60. Miravitlles M, Vogelmeier C, Roche N et al, A review of national guidelines for management 
of COPD in Europe. Eur Respir J 2016;47(2):625-37. 
61. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 
2015;45(2):525-37. 
62. Suissa S, Rossi A, Weaning from inhaled corticosteroids in COPD: the evidence. Eur Respir J 
2015;46(5):1232-5. 
63. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GIONA strategy: a roadmap 
to asthma control. Eur Respir J 2015;46(3):622-39. 
64. Lee AL, Burge A, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane 
Database Syst Rev 2013;5:CD008351. 
65. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect 
of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 
2012;106(5):661-7. 
66. Bilton D, Daviskas E, Anderson SD et al. Phase 3 randomized study of the efficacy and safety 
of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis 
bronchiectasis. Chest 2013;144(1):215-25. 
67. Bilton D, Tino G, Barker AF et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a 
randomised, controlled trial. Thorax 2014; 69(12):1073-9.  
68. Iwagami M, Mansfield K, Quint J et al. Diagnosis of acute kidney injury and its associated 
with in-hospital mortality in patients with infective exacerbations of bronchiectasis: cohort 
study from a UK nationwide database. BMC Pulm Med 2016;16:14.  
69. Bilton D, Henig N, Morrissey B, Gottfried M. Addition of inhaled tobramycin to ciprofloxacin 
for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.Chest 
2006;130(5):1503-10. 
70. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic 
fibrosiss bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1108-15. 
71. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-
cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. 
Thorax 2013;68(9):812-7. 
72. De Soyza A, Pavord I, Elborn JS et al. A randomised, placebo-controlled study of the CXCR2 
antagonist AZD5069 in bronchiectasis. Eur Respir J 2015;46(4):1021-32. 
**RCT of a novel therapy in bronchiectasis, demonstating the importance of neutrophils in 
controlling airway infection as well as in exacerbating disease. 
73. Aliberti S, Masefield S, Polverino E et al. Research priorities in bronchiectasis: a consensus 
statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016; 48(3):632-
47. 
*An international consensus on the key research priorities in the field 
74. Aksamit TR, O'Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels ML, Johnson M, Eden E, 
Griffith D, Knowles M, Metersky M, Salathe M, Thomashow B, Tino G, Turino G, Carretta B, 
Daley CL Adult bronchiectasis patients: a first look at the United States Bronchiectasis 
Research Registry. Chest 2016 in press. 
**a key publication in the field, demonstrating the characteristics of the US bronchiectasis 
population.  
75. Chalmers JD, Aliberti S, Polverino E et al. The EMBARC European Bronchiectasis Registry: 
Protocol for an international observational study. ERJ Open Research 2016;2(1):00081-2015. 
 
 
 
Figure 1. The vicious cycle of bronchiectasis and the drivers of exacerbation.  
 Figure 2. A model protocol for the use of inhaled and oral antibiotic treatment for patients with 
frequent exacerbations of bronchiectasis.  


